Mechanism-First Psychobiotics: Fermented Vegetables, Dairy, and Soy for Depression and Anxiety

1. Introduction

Depression and anxiety increasingly read as vascular inflammatory syndromes as much as brain-limited disorders, with chronic stress, hypothalamic–pituitary–adrenal (HPA) and autonomic imbalance, immune dysregulation, platelet activation, and endothelial injury converging on microvascular dysfunction and blood-brain barrier (BBB) vulnerability [1,2,3]. Population and clinical studies link depressive disorder to composite signatures of low-grade inflammation and endothelial activation, while mechanistic models implicate nitric oxide (NO) biology, nuclear factor kappa B (NF-κB) signaling, and kynurenine (KYN) pathway diversion as shared substrates of mood symptoms and cardiometabolic risk [2,3,4]. In parallel, psychobiotic research has shifted toward microbiome metabolites as actionable mediators [5,6,7]. This review therefore frames fermented foods as metabolite-defined interventions, motivates platform selection, and sets clear objectives for a mechanism-first synthesis [6,7,8].

1.1. Why Depression/Anxiety Belongs in a Vascular Remodeling Issue

A substantial subset of depression and anxiety co-occurs with cardiometabolic and cerebrovascular risk, suggesting shared upstream biology rather than mere comorbidity [1,2,3]. In a remodeling-centered Special Issue, this motivates focusing on vascular substrates, especially the endothelium, as mediators that shape both brain-relevant inflammation and cardio–cerebrovascular outcomes [2,3,9]. Across clinical cohorts and population studies, mood syndromes frequently align with a vascular inflammatory phenotype in which low-grade immune activation runs in parallel with endothelial activation, platelet priming, and microvascular dysfunction [2,3,10]. In older adults, small-vessel brain disease and white-matter lesions track with late-life depression, supporting vascular depression models in which hypoperfusion and barrier vulnerability intersect with neuroimmune stress responses [2,11,12,13].

Endothelial activation and microvascular dysfunction provide a plausible mechanistic bridge between peripheral inflammatory tone and brain vulnerability, particularly in symptom profiles marked by fatigue, sleep disruption, and stress reactivity [2,3,14,15,16]. Meta-analytic and epidemiologic evidence links depressive symptoms to peripheral and cerebral microvascular injury, including impaired retinal reactivity, elevated endothelial biomarkers, white-matter hyperintensities, microbleeds, and infarcts [2,9,12]. Experimental studies add causality: chronic stress can remodel brain endothelium through vascular endothelial growth factor (VEGF) signaling and tight-junction disruption, increasing BBB permeability and enabling cytokine entry into mood-relevant circuits; conversely, restoring NO dependent microvascular function can reverse stress-related behavioral phenotypes [1,5,14]. These findings elevate the neurovascular unit from a correlational bystander to a testable mediator.

Immunothrombosis offers a convergent framework in which endothelium, platelets, and innate immunity form a coupled system that can influence cerebral perfusion, BBB integrity, and neuroimmune signaling relevant to mood [10,17,18,19]. Human data further suggest that mood symptoms track with vascular remodeling and a prothrombotic milieu in high-risk states such as post-myocardial infarction, where arterial stiffness and fibrinogen changes co-occur with anxiety and depression [10,20,21]. Taken together, the key implication for psychobiotics is methodological: interventions should be evaluated not only by symptom change but also by measurable engagement of barrier, endothelial, and thrombo-inflammatory pathways that define remodeling risk, ideally coupled to microbiome-metabolite readouts to support mechanistic inference rather than parallel association stories [5,6,8].

1.2. What “Mechanism-First Psychobiotics” Means (And What It Excludes)

“Mechanism-first psychobiotics” treats fermented-food interventions as mechanistically specified agents, defined by strain identity, quantifiable metabolite outputs, or reproducible chemical fingerprints, and anchored to demonstrable host target engagement [6,22,23]. This framing responds to a recurring limitation in the literature: taxonomy-heavy narratives and symptom-only trials often cannot distinguish causation from coincidence when closely related strains differ in bioactive capacity [6,22,24]. The definition shifts the field toward testable causal chains linking exposure to immune, endocrine, metabolic, and neuroactive pathways relevant to depression and anxiety [25,26,27].

In this framework, “psychobiotic” stops being a broad category term and becomes an operational designation that requires explicit strain or metabolite specification plus biomarker-based evidence that the intended pathway is actually engaged [22,27,28] Fermented foods differ from both general “healthy diets” and capsule probiotics because fermentation generates new chemical entities and reshapes matrix bioaccessibility, altering when and where metabolites are encountered along the gut [6,22,24]. This distinction is mechanistically consequential. Immune receptors, endothelial programs, and neuroimmune mediators often respond to exposure kinetics, dose profiles, and sites of release as much as to the molecular identity itself. The effects of fermented foods cannot be inferred from food labels or taxonomy alone but must be interpreted through quantifiable exposure modules [22,24,29]. Extending this logic, translation of microbiome–gut–brain axis research into clinically meaningful strategies requires moving beyond capsule-based interventions toward real dietary exposures, where food matrices, fermentation chemistry, and metabolite kinetics jointly determine biological effects [6,24,30,31,32]. Fermented foods such as kefir, kimchi, and fermented soy products therefore function not as generic “healthy foods,” but as complex delivery systems that combine metabolite provision, substrate steering, and ecological modulation across the gut–vascular–brain axis [3,5,6,24,33].

To meet that standard, studies must show target engagement by quantifying in vivo metabolite modules and coherently linking them to barrier, endothelial, and inflammatory readouts that plausibly carry gut signals into vascular and brain vulnerability [6,25,26]. In practice, this means tracking tractable readouts such as short-chain fatty acids (SCFA) and tryptophan (Trp)–indole signatures alongside permeability markers, cytokine panels, and endothelial stress indicators, then mapping them onto symptom domains rather than global scores [25,34,35,36,37,38]. Without this, trials risk becoming interpretable only as behavioral or nutritional interventions rather than as mechanistic tests of microbiome-metabolite biology [6,24,26].

By the same logic, the approach explicitly rejects “more beneficial bacteria” rhetoric, culturally compelling food stories, or unquantified exposure descriptions as mechanistic evidence in the absence of metabolite-resolved pathways, confound control, and phenotype stratification [6,22,24]. Likewise, taxonomy-level claims or multi-strain blends blur strain specificity and dilute causal inference [22,27]. Instead, we prioritize metabolite-defined pathways, confound control (e.g., sodium and biogenic amines), and phenotype stratification to prevent false positives and false negatives in depression/anxiety outcomes [6,24,32].

1.3. Why These Three Product Families

The manuscript centers on three fermented-food platform families because they offer complementary mechanistic leverage: live fermented vegetables primarily reshape barrier ecology through organic acids, fiber-linked substrate flow, and locally produced microbial metabolites, while yogurt and kefir offer pragmatic trial feasibility with standardized comparators and a well-described payload of fermentation-derived peptides and exopolysaccharides (EPS) [6,24,33]. Fermented soy adds peptide-rich biochemical diversity and a distinctive capacity for biotransforming phytochemicals into more bioaccessible derivatives with plausible vascular and immune relevance [6,22]. Using these platforms in parallel allows the field to test whether distinct fermented matrices converge on shared downstream pathways, including endothelial activation, immunothrombosis, and neuroimmune tone, or whether effects remain platform-specific and phenotype-dependent [6,25,26].

This platform set is intentionally representative rather than exhaustive, chosen to make mechanistic claims testable with feasible comparators and measurable exposure fingerprints [6,24]. Accordingly, important fermented foods are not treated as primary case examples here, including natto, kombucha, sourdough, fermented teas, traditional fermented fish sauces, and other regional staples [6,24]. These omissions reflect scope discipline, not a judgment about importance, and the framework is meant to be transferable to additional products when chemistry, confounds, and endpoints can be specified [6,24].

We additionally integrate Brazilian cassava ferments and artisanal cheeses as mechanistic case studies that sharpen the platform logic by highlighting fermentation-driven carbohydrate matrix remodeling and proteolysis-driven peptide ecosystems, respectively [6,24,39]. Soy anchors this extension because it couples peptide density with microbial biotransformation of phytochemicals, yielding aglycones and other derivatives with plausible immunometabolic and vascular relevance [6,22,40]. Across these examples, the key is not culinary identity but measurable effectors, including strain-resolved communities, peptide and EPS signatures, and small-molecule modules that map onto barrier and inflammatory biology [6,25,26]. This broadened platform set supports a more generalizable framework in which fermented foods are classified by quantifiable targets, enabling mechanism-first product selection, metabolite-defined pathway testing, confound control, and phenotype-relevant interpretation of depression/anxiety outcomes (Figure 1).

Box 1. Stop calling it psychobiotic unless.

To keep terminology mechanistically honest, we propose the following minimum criteria. A candidate psychobiotic must be defined by strain identity, metabolite outputs, or a reproducible chemical fingerprint, not by food halo or taxonomy rhetoric. It must demonstrate host target engagement using barrier and vascular readouts that matter for depression and anxiety framed as vascular inflammatory syndromes. At minimum, quantify metabolite modules such as short chain fatty acids and tryptophan indole kynurenine signatures, alongside permeability markers, endothelial activation panels, and thrombo-inflammatory indices. Symptom change should be interpreted by domain and linked to these pathways.

2. Fermented-Food Platforms as Mechanistic Tools

Fermented foods can be viewed as experimental platforms that transform raw ingredients into reproducible exposure systems for probing how microbiome-derived metabolites influence vascular and neuroimmune biology [6,41,42]. Fermentation broadens the bioactive landscape by generating organic acids, peptides, exopolysaccharides, and biotransformed phytochemicals, while also introducing microbial communities capable of reshaping the gut microenvironment, barrier function, and immune and HPA-axis signaling relevant to depression and anxiety [6,41,43]. Since these effects depend strongly on both matrix and process, mechanistic interpretation requires precise product characterization and exposure measurement. Given the breadth of fermented-food diversity, this section focuses on a small set of representative platforms rather than attempting an exhaustive survey. As a result, widely studied products such as natto, kombucha, and sourdough are mentioned mainly for context, despite their clear relevance for future module-based trials. The section therefore proceeds by outlining a three-lever framework, defining the principal chemical consequences of fermentation, examining Brazilian products as illustrative case studies, and establishing the standardization principles needed to preserve mechanistic rigor.

2.1. The Three-Lever Framework (Use Throughout the Review)

Fermentation can be translated into testable psychobiotic biology through three mechanistic levers, each with distinct measurement demands and failure modes [27,44,45]. Metabolite provision is the most direct [25,44,46]. Fermentation-derived small molecules can engage host targets without requiring durable microbial colonization. Across the psychobiotic and fermented-food literature, the most reproducible candidates include organic acids and SCFAs, Trp-derived indole metabolites, and selected neuroactive intermediates that covary with inflammatory tone and stress biology in depression and anxiety [45,47,48]. Treating these as provided effectors tightens inference because the hypothesis becomes dose-linked and falsifiable: exposure must shift first, then intermediates and symptoms can be interpreted as downstream movement [25,46,47]. This lever is strongest when exposure is quantified, since kinetics determine whether metabolites plausibly reach immune, endothelial, or neurovascular interfaces [46,47,49].

Substrate steering acts upstream by reshaping the food matrix and therefore the substrates presented to the colon [27,44,50]. Acidification, partial degradation of fibers and proteins, reduction of antinutrients, and polyphenol biotransformation alter fermentability and bioaccessibility, shifting endogenous production of SCFAs, indoles, bile-acid derivatives, and other host-sensed metabolites [47,51,52]. Metabolomics reinforces this point: process conditions generate distinct small-molecule fingerprints that cannot be inferred from ingredient lists [27,51,53]. The mechanistic prediction is not that fermented foods contain beneficial metabolites, but that they shift metabolite outputs in vivo, often in a diet-dependent manner [44,48,54].

Ecology shaping extends the time horizon. Acids, microbes, and microbial effectors act as selection pressures that recalibrate community function and resilience, even when taxonomic changes look modest [44,49,54]. Fermented foods then operate less as one-off exposures and more as repeat perturbations that favor specific metabolic guilds, alter cross-feeding, and reshape barrier-facing and immune-active outputs relevant to mood [44,47,48]... Durability becomes the discriminant: transient passage may create short-lived functional shifts, whereas repeated exposure can stabilize new behaviors without obvious compositional reorganization [48,49,54]. Because storage, viability, and co-ingredients influence this lever, claims should be anchored to functional readouts rather than compositional snapshots alone [27,44,55]. This ecological perspective also means that fermented foods should be interpreted within whole dietary patterns rather than as isolated items [44,48,54]... In real diets, background fiber availability, protein intake, and matrix co-exposures determine whether fermented foods amplify short-chain fatty acid production, indole signaling, and community resilience, or instead generate weaker, less reproducible effects [48,49,54]. Accordingly, ecological validity is not a soft nutritional add-on; it is part of the mechanism [56,57,58,59,60].

Box 2. Product-family positioning statements (vegetables vs dairy vs soy).

Fermented vegetables function as the barrier and ecology lever: organic acids plus fiber-linked substrate flow reshape luminal pH gradients, tighten gut-barrier tone, and reduce endotoxemia potential that can feed endothelial activation. Yogurt and kefir function as the trial lever: standardized comparators, consistent dosing, and tractable fermentation outputs, especially peptides and exopolysaccharides, make mechanistic target engagement testable. Fermented soy functions as the peptide and immunometabolic lever: proteolysis and phytochemical biotransformation yield bioactive diversity suited to vascular and inflammatory phenotypes.

2.2. Product-Centric Chemistry and “What Actually Changes”

Fermentation across vegetables, dairy, and soy reliably drives acidification, redox shifts, and remodeling of small molecules that redirect both microbial competition and host exposure [27,44,50]. Starter consortia channel carbohydrates into lactic and related acids while releasing acetate, propionate and butyrate precursors, volatile acids, and reactive intermediates such as peroxides and carbonyls [27,44]. Polyphenols shrink into more absorbable phenolic acids with altered activity [40,47,50,52]. Why care? Because luminal pH and organic acid balance tune barrier function and inflammatory set points that ripple toward endothelial behavior [25,44,47].

Fermentation also rewires proteins and polysaccharides. Microbial proteases carve milk and plant substrates into peptide constellations whose sequences depend on strain and process, yielding antioxidant, angiotensin-converting enzyme (ACE) inhibitory, immune, and antithrombotic potential [47,61,62]. At the same time, lactic acid bacteria (LAB) secrete EPS that behave as postbiotic polymers [44,47,61]. They influence mucosal signaling, microbial ecology, and even texture through interactions with proteins [47,61]. Peptide and EPS patterns therefore, act as product identities, measurable and comparable, not vague promises attached to a food name [44,47].

Context changes everything. The same organism or metabolite performs differently depending on the matrix, since fermentation alters bioaccessibility, release kinetics, and chemical companions that govern target engagement [27,47,50]... Gastric handling and digestion then sculpt distinct exposure curves for acids, peptides, lipids, minerals, and phytochemicals [27,47,48]. Human metabolomics confirms that similar nutrient lists can yield divergent systemic footprints [27,51,53]. Plant tissues further complicate matters because bound compounds may appear late, primarily in the colon [27,50,52]. Mechanism-first trials must therefore lock down format and processing, while treating sodium and biogenic amines as active modifiers of effect.

2.3. Brazilian Fermented Platforms (Cassava and Artisanal Cheeses) as Mechanistic Case Studies

Brazilian cassava fermentations offer a mechanistically clean example of fermentation as matrix bioprocessing, where acidification and starch remodeling jointly shape downstream microbial metabolism and barrier-facing hypotheses [63,64]. More broadly, Brazil offers a diverse repertoire of cassava-, dairy-, and cereal-based ferments shaped by spontaneous or semi-controlled fermentation, underscoring how regional products can generate complex biochemical transformations with mechanistic relevance beyond globally standardized models [65,66,67,68]. The inclusion of Brazilian cassava ferments is intentional. They function as a regional stress test for the review’s mechanism-first logic, showing how non-globalized products can still be translated into exposure fingerprints, confound control, and barrier-to-vascular endpoints [67,69]. This choice also signals that other culturally important ferments not covered in depth here, such as natto, injera, idli or dosa batters, kombucha, kvass, and traditional fermented fish sauces, can be evaluated using the same modular framework [67,68]. Across tucupi, puba or carimã, polvilho azedo, and farinha d’água, LAB and yeasts drive a rapid pH drop, generate organic acid profiles, and remodel carbohydrate structure and fermentability [63,64,67]... At the same time, traditional workflows also aim to reduce cyanogenic potential through pressing, washing, fermentation, and, for tucupi, boiling [67,70]. Omics and targeted analytics indicate that these platforms can carry process-sensitive signatures, including carotenoid shifts and low but detectable levels of biogenic amines, with substantial variability across commercial samples [69,71]. Tucupi, puba or carimã, polvilho azedo, and farinha d’água therefore serve as case-study platforms for testing substrate steering and barrier engagement, provided batch chemistry and potential amine or sodium variability are measured [69,70,71]. In addition to acidification and detoxification, these cassava platforms may alter starch structure in ways that increase colonic fermentability and support acetate- and butyrate-linked barrier and metabolic effects, although these outcomes remain strongly process- and microbiota-dependent [63,72,73,74,75].

Brazilian artisanal cheeses, such as queijo Canastra and queijo do Marajó, highlight fermentation as a proteolysis-dominant ecosystem capable of generating high-information peptide and EPS profiles [76,77,78]. These cheeses are included intentionally to broaden the geographic lens beyond the usual Eurocentric “model products” and to show how region-specific fermentation ecologies can be incorporated without inflating the manuscript [76,77,79]. The goal is reader transfer: once the logic is clear for Canastra and Marajó, it becomes easier to recognize and interrogate under-discussed products from other regions [76,77]. Raw-milk technologies and endogenous starters create dense microbial consortia in which LAB and yeasts, shaped by geography, farm practices, and even phage–bacterium dynamics, drive ripening-dependent proteolysis and metabolite succession [76,77,79]. Consistent with this, ripening studies show time-dependent accumulation of water-soluble peptide fractions with antioxidant, ACE-inhibitory, and antimicrobial activities, while isolate screens identify frequent EPS-producing and biopreservative LAB traits [76,78,80]. Yet these platforms are high-variance and carry nontrivial safety constraints. Their mechanistic value is highest when coupled with peptidomic and metabolomic fingerprinting and sodium and biogenic amine reporting, enabling comparison with standardized yogurt-style platforms [77,78,81]. Their peptide repertoires also strengthen the case that artisanal cheeses may influence oxidative balance, inflammatory signaling, and vascular function, although this promise remains inseparable from the need for tight safety and batch standardization [78,80,82,83,84,85]. Regional and indigenous fermented preparations likely share these same core mechanistic themes—metabolite production, ecological modulation, and host immune interaction—even where formal psychobiotic evidence remains sparse [67,68]. In Table 1, the product platforms are shown.

Image credit (Wikimedia Commons): Kimchi, Baptori, Paris 20 September 2016, photo by Guilhem Vellut, Wikimedia Commons, https://commons.wikimedia.org/wiki/File:Kimchi,_Baptori,_Paris_20_September_2016.jpg, licensed under Creative Commons Attribution 2.0 Generic (CC BY 2.0), https://creativecommons.org/licenses/by/2.0. (Wikimedia Commons). Fresh Sauerkraut in the market Danilovsky Market, Moscow, Russia (25840010287).jpg, photo by Andrey Filippov 安德烈, Wikimedia Commons, https://commons.wikimedia.org/wiki/File:Fresh_Sauerkraut_in_the_market_Danilovsky_Market,_Moscow,_Russia_(25840010287).jpg, licensed under Creative Commons Attribution 2.0 Generic (CC BY 2.0), https://creativecommons.org/licenses/by/2.0. Yogurt, Samoa, Yoggi original.JPG, photo by Jin Zan, Wikimedia Commons, https://commons.wikimedia.org/wiki/File:Yogurt,_Samoa,_Yoggi_original.JPG, licensed under Creative Commons Attribution ShareAlike 4.0 International (CC BY-SA 4.0), https://creativecommons.org/licenses/by-sa/4.0. Kefir 1.jpg, photo by Scudsvlad, Wikimedia Commons, https://commons.wikimedia.org/wiki/File:Kefir_1.jpg, licensed under Creative Commons Attribution ShareAlike 4.0 International (CC BY-SA 4.0), https://creativecommons.org/licenses/by-sa/4.0. (Wikimedia Commons) Miso 003.jpg, Red Miso, by oofree.net, Wikimedia Commons, https://commons.wikimedia.org/wiki/File:Miso_003.jpg, licensed under Creative Commons CC0 1.0 Universal Public Domain Dedication, https://creativecommons.org/publicdomain/zero/1.0/. (Wikimedia Commons) Tempeh raw.jpg, photo by Christian Franke, Wikimedia Commons, https://commons.wikimedia.org/wiki/File:Tempeh_raw.jpg, licensed under Creative Commons Attribution ShareAlike 3.0 Unported (CC BY SA 3.0), https://creativecommons.org/licenses/by-sa/3.0. (commons.wikimedia.org) Polvilho azedo.jpg, photo by Lichinga, Wikimedia Commons, https://commons.wikimedia.org/wiki/File:Polvilho_azedo.jpg, licensed under Creative Commons Attribution ShareAlike 4.0 International (CC BY-SA 4.0), https://creativecommons.org/licenses/by-sa/4.0/. (Wikimedia Commons) Cropped and resized for layout; changes indicated; license terms retained. (Wikimedia Commons) Farinha de mandioca d’agua paraense (6892622493).jpg, photo by Monica Kaneko, Wikimedia Commons, https://commons.wikimedia.org/wiki/File:Farinha_de_mandioca_d%27agua_paraense_(6892622493).jpg, licensed under Creative Commons Attribution ShareAlike 2.0 Generic (CC BY-SA 2.0), https://creativecommons.org/licenses/by-sa/2.0/. (commons.wikimedia.org) Queijo canastra, Minas Gerais.jpg, photo by Marcelo Costa, Wikimedia Commons, https://commons.wikimedia.org/wiki/File:Queijo_canastra,_Minas_Gerais.jpg, licensed under Creative Commons Attribution 2.0 Generic (CC BY 2.0), https://creativecommons.org/licenses/by/2.0. (Wikimedia Commons) Photo licensed from Vecteezy under the Free License. Copyright remains with the contributor. Source: Vecteezy.com. https://www.vecteezy.com/free-photos/cellar">Cellar Stock photos by Vecteezy Cropped and resized for layout; no substantive content changed. CFU, colony-forming units; EPS, exopolysaccharides; FXR, farnesoid X receptor; g/day, grams per day; LAB, lactic acid bacteria; LBP, lipopolysaccharide-binding protein; NO, nitric oxide; pH, potential of hydrogen; ROS, reactive oxygen species; SCFA, short-chain fatty acid; sCD14, soluble cluster of differentiation 14; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; TGR5, Takeda G protein-coupled receptor 5.

2.4. Standardization and Safety That Directly Affect Mechanisms

Standardization is not bureaucracy. It is the gatekeeper of mechanism. When viability, acid load, salt, or storage drift, the very pathways later measured as outcomes may already be pre-shifted. Fermentation products arise from community ecology plus process control, so minor changes in oxygen, temperature, or time can redirect networks and rewrite the delivered mix of acids, peptides, EPS, amines, and transformed phytochemicals Without tight definitions, dose response collapses and a null result says nothing [101,102].

A minimum specification keeps inference alive. Report identity, preparation, serving size, viability status, pH, and a compact organic acid profile. Add whether the product is live or heat treated, its age, storage conditions, and any factors known to influence metabolite drift Safety chemistry belongs in the same frame. Sodium and targeted biogenic amines must be visible, along with routine pathogen screening If omics are deployed, analytical pipelines and quality thresholds should be explicit [38,103,104].

Why emphasize salt and amines? Because they alter vascular tone, arousal, and sleep, easily imitating benefit or harm.Comparator logic therefore matches exposure, not food names. Align sodium, track amines, and design arms that can disentangle fermentation from parallel variables. More broadly, causal inference is also limited by product heterogeneity, dietary confounding, small sample sizes, and short intervention durations, which together make symptom-only findings particularly vulnerable to misinterpretation [42,89]. In Table 2, it is possible to find information about components in fermented foods.

3. The Tri-Barrier Remodeling Axis: Gut ↔ Endothelium ↔ Blood-Brain Barrier

The tri-barrier remodeling axis frames the gut epithelium, systemic endothelium, and BBB as interlocked control surfaces that convert luminal chemistry into vascular and neuroimmune states, shaping depression and anxiety [135,136,137]. Events upstream set boundary conditions downstream [135,138,139]. A shift in permeability or mucosal signaling can recalibrate cytokine tone, alter endothelial behavior, and ultimately influence neural vulnerability [135,136,140]. Apparent inconsistencies across fermented foods become predictable when exposure kinetics, matrices, storage conditions, and comparators are misaligned, because each variable shifts where and how the signal lands [139,140]... A mechanism-first strategy therefore measures the interfaces in sequence rather than chasing symptoms [135,139,140]. The roadmap proceeds from epithelial sensing to vascular activation to cerebral gating, while aligning vegetables, dairy, and soy with the barrier tier they most plausibly influence and thus must be tested.

3.1. Gut Barrier: Pattern-Recognition Receptor (PRR) Signaling, Tight Junctions, Mucosal Immunity

Pattern recognition receptors at the epithelial frontier act as the master rheostat for the barrier network [138,141,142]. They convert contact with microbes into alarm signals, cytokine gradients, and recruitment cues for myeloid cells [141,142,143]. If that sensing skews toward danger, endotoxin tone lingers, repair falters, and vascular beds downstream inherit a primed phenotype [137,138,140]... The decisive experiment is therefore exposure biology, not taxonomy [141]. Did receptor-relevant ligands fall? Did signaling go quiet? Markers such as lipopolysaccharide (LPS)-inducing protein, soluble CD14, Toll-like receptor-induced cytokines, and inflammasome products sit closest to ignition and define whether immune traffic has truly slowed [140,144,145].

Once alarms sound, junctions determine spread. Claudin pores and inducible leak pathways respond to inflammatory kinases, reorganizing occludin and zonula occludens 1 (ZO-1) and allowing graded antigen passage into tissue and blood [140,144,146]. This is a dimmer, not a switch [139,140,144]. Small defects can have large consequences for cytokines, keeping innate cells on patrol and perpetuating signals that later masquerade as primary brain pathology [137,138,140]. Mechanistic inference strengthens when symptoms travel with measures of permeability adjacent to the gut, such as zonulin-related signatures, intestinal fatty acid-binding protein, and direct assessments of junctional architecture across experimental systems [144,147,148].

Mucus provides the staging ground. Goblet cells invest energy to maintain distance between microbes and epithelium, a task reinforced by butyrate and indole chemistry that supports MUC2 expression and tolerance programs [138,149,150]. Diets that favor mucin degraders collapse that buffer [138,149]. Bacteria approach, receptors engage, and endotoxin pressure rises [138,141,149]. Immune governance then chooses containment or escalation [138,143]. Secretory IgA and antimicrobial peptides can quarantine exposure, yet persistent NF-κB bias drives interleukin (IL)-1β, IL-6, and T helper 17 cell (Th17) polarization [138,141]. Tracking IgA patterns, regenerating islet-derived protein 3 family (Reg3) activity, and Treg balance clarifies whether upstream sparks are extinguished or continue to fuel systemic flow toward vascular and neural interfaces [138,141,149].

3.2. Endothelium: Activation (Intercellular Adhesion Molecule (ICAM)/ Vascular Cell Adhesion Molecule (VCAM)), Glycocalyx Loss, Nitric Oxide (NO) Biology

Endothelium converts diffuse inflammation into movement. Cytokines and danger signals drive cells toward adhesion, leak, and trafficking programs, characterized by intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and selectins [151,152,153]. That pivot choreographs rolling, arrest, and transmigration while altering permeability and regional oxygen delivery [151,154,155]. Small molecular nudges can therefore magnify into perfusion deficits and self-reinforcing inflammatory loops [155,156]. Mechanism-driven trials should treat soluble and surface adhesion molecules, along with chemokine gradients, as scaling factors of vascular stress [152,153]. In brain-facing territories, the same biology shapes the susceptibility of microvessels that nourish circuits governing affect, motivation, and cognition [15,25,157].

Immunothrombosis shows what happens next. The endothelial stage recruits platelets and neutrophils, translating tone into obstruction [158,159]. Glycocalyx erosion removes anticoagulant protection, unmasks adhesion receptors, and weakens shear-dependent NO signaling [155,159]. The surface becomes sticky. Von Willebrand factor (vWF) release, P selectin exposure, and tissue factor activity intensify capture, while extracellular traps stabilize clots and concentrate enzymes that injure nearby cells [158,160,161]. Measuring vWF handling, fibrinogen, platelet leukocyte aggregates, and neutrophil extracellular trap (NET) products alongside adhesion markers turns an abstract risk into a trackable mechanism with therapeutic leverage [158,160,161].

Loss of glycocalyx is not decorative damage. Heparan sulfate-rich structures normally sense flow and relay it to endothelial nitric oxide synthase (eNOS), sustaining dilation and quelling leukocyte contact [156,162,163]. Oxidative stress and complement disturb this conversation. As the layer thins, permeability rises, and procoagulant motifs dominate [155,159]. Biomarkers such as syndecan-1 or hyaluronan help determine whether improvement reflects true endothelial repair or merely quieter upstream inflammation [155,159]. Pair them with functional tests, and the picture sharpens [162,163].

NO then decides performance. Adequate substrate and redox balance favor relaxation, efficient exchange, and coordinated neurovascular coupling [151,156,162]. Depletion of tetrahydrobiopterin, accumulation of asymmetric dimethylarginine (ADMA), or excess reactive oxygen species (ROS) diverts eNOS toward superoxide production, reducing bioavailability and stiffening the circuit [151,162,163]. Fatigue, stress sensitivity, and cognitive fog become plausible vascular consequences [157,163]. Because diet-derived metabolites can influence arginase flux and oxidative tone, trials gain power when NO metabolites are linked to redox indices and measures of vascular reactivity [151,156,162]. While the tri-barrier model organizes the pathway from gut chemistry to vascular and immune signaling, its translational value depends on integration with classical neurobiology [6,25,157]. Peripheral inflammatory and endothelial shifts influence central neurotransmission through serotonin–kynurenine balance, dopaminergic circuit function, and HPA-axis regulation, so barrier and vascular readouts should be interpreted as upstream modulators of brain-relevant processes rather than as isolated peripheral events [6,157]. This becomes especially relevant when increased kynurenine-pathway activity coincides with reduced serotonin availability and the accumulation of neuroactive metabolites that can alter glutamatergic tone and cause neurotoxicity [4,16,157,164,165,166,167,168,169]. In parallel, inflammatory signaling can suppress BDNF-related plasticity, providing a mechanistic bridge between peripheral vascular-immunometabolic disturbances and depressive phenotypes [6,25,170].

Fermented foods add specificity to this framework by acting as structured delivery systems of neuroactive precursors and microbiome-modulating signals that can reshape these pathways [6,164,171]. Fermentation-derived SCFAs and tryptophan-derived indoles may indirectly influence central neurotransmission by modulating peripheral immune tone and blood–brain barrier permeability, while dairy- and soy-derived peptides may preserve endothelial nitric oxide signaling and cerebral perfusion, indirectly supporting dopaminergic and limbic circuit function [25,152,157,172,173]. These vascular–neural intersections are particularly relevant to symptom domains such as fatigue, anhedonia, and cognitive slowing [6,19,157].

Fermented foods may also influence stress circuitry and neuroplasticity through coupled metabolic and endocrine effects [6,157,164]. By lowering inflammatory and oxidative stress and modulating vagal and HPA-axis signaling, fermentation-derived metabolite networks may create conditions more permissive for BDNF-linked plasticity and resilience [6,19,25,170,174,175,176,177,178]. The key point is that these effects are unlikely to be reducible to single compounds; they arise from coordinated exposure kinetics within a fermented matrix [6,152]. For that reason, fermented-food metabolite modules should be interpreted not only through barrier and endothelial endpoints, but also through their capacity to shape neurotransmission, stress circuitry, and neuroplasticity [6,15,152,164,168,170,178,179].

3.3. BBB: Permeability, Microglial Priming, Stress Circuitry

The blood-brain barrier is best viewed as the brain’s specialized endothelium, extending systemic vascular logic into neural territory [180,181,182]. Claudin-5, occludin, and ZO scaffolds create high electrical resistance, reinforced by VE cadherin, while solute carriers and ABC efflux pumps govern selective entry under conditions of normally low transcytosis [183,184]. Inflammation and metabolic stress breach this control through two distinct routes [181,183,185]. Junctions can be relocalized or cleaved, but exposure can also shift without obvious leak when vesicular trafficking rises, and transporter programs are rewired [183,185,186]. For -first inference, BBB integrity must be measured directly, using permeability proxies and barrier-linked molecular signatures rather than assuming peripheral changes equal brain delivery [13,40,169,181,186,187].

Once gating loosens, microglia become the amplifier. Perivascular microglia can initially stabilize vessel contacts and junctional proteins, then pivot toward breakdown, releasing ROS, IL-1β, tumor necrosis factor alpha (TNF-α), matrix metalloproteinase 9 (MMP-9), and chemokines that disrupt astrocytic endfeet, pericyte control of flow, and synaptic homeostasis [175,188,189,190]. That primed state makes later stressors disproportionately potent, translating modest peripheral inflammation into larger circuit-level effects relevant to depression and anxiety [14,188,191]. Pairing BBB readouts with microglial activation markers and inflammatory mediators clarifies whether an intervention strengthens interfaces upstream or only dampens downstream neuroimmune reactivity [13,177,178,188,189,192].

Neurovascular remodeling is not uniform. Limbic and prefrontal circuits gate HPA output differently, so identical blood signals can yield distinct endothelial and junctional responses across medial prefrontal cortex, hippocampus, amygdala, and nucleus accumbens [14,191,193]. Claudin 5-centered patterns, hypoperfusion, VEGF tone, and local cytokines repeatedly track susceptibility versus resilience [14,180,181]. Aligning mechanistic endpoints with symptom domains such as fatigue, sleep disruption, and stress reactivity turns heterogeneity into interpretable biology and guides which barrier layer an intervention most plausibly engages [14,191,193].

3.4. Product Mapping: Which Fermented Foods Most Plausibly Support Which Barrier Layer

Fermented vegetables most plausibly engage the gut barrier layer by combining acidity, fiber-associated substrate steering, and LAB-driven ecology, which can reduce endotoxemia-linked signaling upstream of endothelial activation [185]. In practice, these platforms deliver a barrier-active metabolome enriched in lactic acid and plant-derived co-metabolites, while simultaneously promoting colonic SCFA patterns, often with butyrate support, that stabilize epithelial energetics and mucus output [185]. Cell and animal models show that fermented vegetable matrices and their fermentates preserve transepithelial electrical resistance (TEER) under cytokine or LPS stress and upregulate junctional programs such as ZO-1 and claudin modules [183,186,190]. This predicts measurable shifts in permeability and pattern-recognition receptor (PRR)-tone markers, plus downstream reductions in endothelial activation and immunothrombotic readouts, providing a clear mechanistic chain rather than a generic “healthy diet” narrative [185,188,190].

Kimchi and related fermented vegetables further exemplify this upstream logic because their effects are likely to center on barrier reinforcement and attenuation of endotoxemia-linked signaling [185]. By supporting short-chain fatty acid and indole production, improving epithelial integrity, and lowering systemic inflammatory tone, these matrices may, in turn, secondarily reduce kynurenine-pathway activation and preserve a more favorable serotonergic and neuroimmune balance [185]. This makes fermented vegetables especially attractive when the dominant hypothesis concerns early gut–vascular gating rather than downstream neuroactive peptide delivery [185].

Fermented dairy and soy products extend the mapping from barrier containment to systemic signaling, because dairy is a trial-friendly matrix rich in peptide and EPS effectors, while soy adds peptide diversity plus biotransformed phytochemicals that intersect with immunometabolic pathways [186,190]. Across yogurts, kefir, and fermented whey, defined starters and processing can reproducibly tighten junctional programs, raise IgA- and Treg-linked tone, and lower cytokine spillover, making peptide and EPS fingerprints plausible effectors rather than background noise [186,190].

Kefir is a particularly useful trial-facing dairy platform because its symbiotic consortium, kefiran-rich matrix, and reproducible fermentation outputs create a tractable combination of peptides, exopolysaccharides, organic acids, and low-level fermentation byproducts [186,190]. Experimental and early clinical data suggest that these outputs may reduce inflammatory tone and oxidative stress while preserving endothelial nitric oxide bioavailability and microvascular function [186,188,190]. In neurobiological terms, that profile makes kefir especially relevant to symptom domains such as fatigue, stress reactivity, and anhedonia, where immune, vascular, and limbic mechanisms converge [14,188,191].

Soy ferments, exemplified by fermented soymilk in colitis models, similarly restore occludin and SCFA profiles but layer on remodeled isoflavones and other small molecules that can engage bile-acid, AhR, and metabolic signaling [190]. The practical implication is to choose platforms based on the dominant hypothesis: dairy when immune tone and peptide/EPS fingerprints are central, soy when metabolite diversity and immunometabolic signaling are prioritized, and then test both against shared endothelial and BBB readouts to establish barrier-to-brain mechanistic continuity [14,176,188,190].

Fermented soy products add a complementary immunometabolic layer because fermentation increases isoflavone bioavailability and generates peptide-rich profiles with antioxidant and ACE-inhibitory properties [190,194,195]. Through these effects, soy ferments may influence vascular tone, bile acid signaling, aryl hydrocarbon receptor biology, and systemic inflammatory load, making them especially relevant in depressive phenotypes coupled to metabolic dysfunction [14,188,190]. In that sense, fermented soy can be positioned as a bridge matrix linking endocrine, vascular, and neuroimmune regulation [14,176,188,190].

4. Metabolite Modules (Core Mechanistic Engine)

Metabolite modules are the working units of mechanism in fermented food research: they function like dosing readouts, capturing conserved receptor-facing chemistry that can be quantified, compared across products, and aligned with causal intermediates [41,61]. This module's first stance matches modern psychiatric metabolomics, where pathway ensembles explain variation in depression and anxiety far better than single analytes or broad diet labels [196,197]. Across cohorts and experimental systems, recurrent clusters point to gut-derived co-metabolites and immunometabolic hubs, most notably SCFAs, Trp derivatives, and bile acid signaling, which then shape barrier integrity, endothelial activation, and higher-order integrative endpoints such as immunothrombosis and biological aging pace [198,199]. Accordingly, each subsection treats a module as a testable exposure unit with explicit kinetics, confounds, and mapping to shared gut, vascular, and BBB panels [35,200]. We begin with SCFAs because they are the most conserved fermentation to host signal and the simplest to track longitudinally.

Figure 2 presents the metabolite modulation and receptor targets linking fermented-food platforms to vascular and brain-relevant pathways.

4.1. Short-Chain Fatty Acids (SCFAs): G Protein-Coupled Receptor (GPCR) + Histone Deacetylase (HDAC) Biology

SCFAs are best treated as dosing-grade concentration time exposures, not as a vague badge of “healthy fermentation” [201,202,203]. Fiber and resistant starch set the production rate, baseline guilds and cross-feeding set the acetate:propionate:butyrate pattern, and transit determines where along the colon each peaks [201,204,205]. Host handling then filters the signal: colonocytes avidly oxidize butyrate, propionate is largely routed to the liver, and acetate reaches peripheral beds more readily [201,206,207]. A fecal rise, therefore, is not the same as systemic delivery, and timing can matter even more than magnitude in vivo [201,202,203]. This creates a clean causal question in trials: are SCFAs primarily provided by the product’s chemistry, or produced because the intervention steers substrates toward saccharolytic metabolism? The answer determines what “dose” means, what compartment matters, and what should be measured [201,202]. Brazilian cassava ferments offer a clean SCFA-facing case because they are starch-dominant platforms where fermentation changes fermentability and acid load more than it “adds microbes” [208,209,210]. Tucupi and puba/carimã, for example, primarily test whether a process-defined carbohydrate matrix can shift fecal acetate–propionate–butyrate patterns under a fiber-controlled background [208,209]. Because cassava workflows also target cyanogenic risk reduction, chemistry release criteria should include organic acids, along with a safety-focused processing marker set, before inferring physiology [209,210,211].

Mechanistically, SCFAs translate fermentation into rapid mucosal decisions through FFAR2 (GPR43), FFAR3 (GPR41), and G protein-coupled receptor 109A (GPR109A) [212,213,214]. These GPCRs tune cAMP and Ca2⁺ signaling, bias mitogen-activated protein kinase (MAPK) and NF-κB programs, and reshape chemotaxis, enteroendocrine outputs, and cytokine tone across epithelial and myeloid compartments [212,215,216]. Butyrate, and to a lesser extent propionate, also enter cells via monocarboxylate transporters and inhibit HDACs, changing chromatin accessibility and slowing inflammatory transcriptional cycles [212,215,216]. Read this as one chain, not two stories: speciation and kinetics set receptor engagement and intracellular exposure, which then reweight IL-10 and IL-22 support, restrain IL-6 and TNF-α, and favor Treg-competent programs [213,215,216]. The goal is not to promise effective rescue, but to demonstrate receptor biology that can plausibly propagate [213,214]. Stress physiology follows the immune set point, not the other way around [207,213]. Mood outcomes sit downstream; target engagement lives near the receptors, transporters, and chromatin [213,215,216].

The barrier gate is where SCFAs become causally interpretable [214]. By supporting mucus energetics, tight-junction organization, and epithelial repair programs, SCFAs reduce the probability that luminal products will reach lamina propria sensors and the bloodstream [213,214]. A mechanism-first study therefore expects coordinated movement in containment markers before symptoms: improved TEER or reduced fluorescein isothiocyanate (FITC)-dextran flux in models, tighter junctional localization of claudins, occludin, and ZO-1, and, in humans, lower permeability-adjacent signals such as intestinal fatty acid-binding protein (I-FABP) or zonulin-linked signatures [213,214]. Add a simple immune traffic panel: LBP and soluble cluster of differentiation 14 (sCD14) for translocation pressure, plus a cytokine pattern consistent with reduced PRR drive [207,213]. If possible, include fecal calprotectin or a mucus marker to disambiguate epithelial injury from immune activation over a meaningful time, and confirm that branched-chain fatty acids do not rise as proteolysis drifts aligned with SCFA kinetics [206,212,213].

Once containment improves, endothelial biology becomes the vascular hinge that converts inflammatory tone into perfusion stability, thrombosis propensity, and aging-like programs [207,217]. SCFAs can dampen LPS- or TNF-α-driven endothelial activation by reducing NF-κB and MAPK outputs, often with lower ICAM-1, VCAM-1, and E-selectin signaling and fewer adhesive encounters [215,216,217]. In parallel, redox shifts preserve NO bioavailability by limiting ROS scavenging and supporting eNOS coupling, both of which are important for flow and neurovascular reserve [207,213]. The measurable prediction is a convergent phenotype: reduced adhesion programs, improved NO and oxidative balance, and less platelet priming that otherwise couples to NET formation, vWF handling, and microthrombi [213,217]. Pair adhesion markers with a platelet activation index to show translation from inflammation into vascular mechanics [217]. In that framing, vascular stabilization is a plausible substrate for reduced fatigue, steadier sleep, and less stress reactivity even before mood scales move [207,213].

Minimum specification should be strict [202,218]. Fingerprint the product with pH plus an organic-acid panel, then quantify stool SCFA speciation and pair it with plasma levels or postprandial sampling to capture kinetics [202,203]. Standardize pre-analytics: stool mass, rapid stabilization, cold chain, and zero tolerance for freeze-thaw drift [202]. Match comparators for calories, fiber grams, and type, and sodium, and record alcohol, antibiotics, and metformin because they reroute fermentation [201,204]. Start with SCFAs because they are the most conserved fermentation-to-host signal and the easiest module to quantify longitudinally [204,213,214] (Table 3). Once energy and barrier containment are anchored, the next module asks a different question: how does fermentation reroute Trp signaling toward immune tolerance or neuroinflammatory drift?

4.2. Tryptophan (Trp)/Indole Axis: Aryl Hydrocarbon Receptor (AhR) Signaling and Neuroimmune Gating

Trp is best treated as an allocation problem, not a nutrient tally [226,240,241]. The same dietary pool can be routed toward microbial indole derivatives that signal tolerance, toward host KYN chemistry that often tracks immune activation, or toward serotonin precursors with gut and platelet relevance [4,165,166,226,240,242]. Fermentation and the background diet shift that is routed by changing substrate availability, redox tone, and the microbes and enzymes that compete for Trp [243,244,245]. For mechanism-first work, the exposure unit is therefore a metabolite module, an interpretable mixture whose concentration and timing can be tracked across compartments rather than inferred from a food label [226,246,247]. This framing turns Trp effects into testable hypotheses about where flux goes and why, before any symptom story is told [16,166,167,168,241,245,248].

At the gut interface, indole-class ligands act as a practical switchboard because they can engage aryl hydrocarbon receptor (AhR) programs that stabilize containment [226,240,241]. When indole-3-aldehyde, indole-3-lactic acid (ILA), indole-3-acetic acid (IAA), or indole-3-propionic acid (IPA) rise, the predicted direction is not mood improvement but quieter immune traffic: tighter junction architecture, reinforced mucus and epithelial stress defenses, and stronger IL-22 centered repair and antimicrobial tone [240,241,249]. Those outputs matter because they reduce the probability that PRR sensing is repeatedly tipped toward alarm [240,241,250]. In other words, AhR signaling helps convert luminal chemistry into tolerogenic set points, with downstream effects on Th17 versus Treg balance and IgA mediated quarantine [240,241,250]. This is why barrier and mucosal immunity belong in the same paragraph as indoles: they are the mechanistic gate that decides whether signals stay local or spill systemically [240,241,251].

Neurovascular relevance follows the same logic, just in a different anatomical compartment [248,251,252]. If indole-driven containment reduces endotoxin and cytokine drift, the BBB and the neurovascular unit receive fewer priming cues that would otherwise bias microglia toward exaggerated responses to stress or infection [248,251,252]. Some indole-class ligands can also act more directly, shaping AhR-dependent inflammatory programs in microglia and astrocytes, which then modulate junctional support, chemokine tone, and synaptic vulnerability [248,251,252]. The key point is continuity: BBB gating is an extension of systemic endothelial biology, so shifts in indole modules should be read alongside permeability proxies and vascular activation, not in isolation [247,248,251]. That design makes it possible to distinguish upstream containment from downstream neuroimmune dampening, and to time-stamp where the signal first appears [247,248,251].

Minimum measurement is straightforward but non-negotiable [226,241,247]. Define dose as a concentration time profile, captured by time-resolved stool or fecal water indoles plus urine and plasma panels that report absorption and systemic handling [226,241,251]. A compact targeted set can include Trp, KYN, and the KYN-to-Trp ratio, plus indole, IAA, IPA, ILA, indole-3-aldehyde, and tryptamine, ideally with a parallel functional readout, such as AhR reporter activity or CYP1A1 induction [226,247,253]. Sampling should be aligned to product kinetics because matrix and processing change where and when ligands appear, and because colon production and host clearance are not synchronized [243,244,253]. Pair this with early downstream markers that should move first, such as IL-22, antimicrobial peptide surrogates, and barrier-adjacent readouts like zonulin-linked signatures or I-FABP, so attribution does not depend on symptoms [240,241,249].

Failure modes are predictable and preventable [241,243,244]. High protein load, low fiber context, or antibiotic and metformin exposure can reroute flux and flatten signals, while uncontrolled fermentation can add confounding amines and acids that change sleep and arousal [241,243,244]. The antidote is comparator discipline and diet context reporting, plus prespecified thresholds for what counts as a meaningful module shift, not just a p-value [241,243,244]. If indoles tune immune set points, bile acids act like endocrine wiring, translating microbial chemistry into host metabolism and vascular tone [247,249,251].

4.3. Bile Acid Signaling: Farnesoid X Receptor (FXR)/Takeda G Protein-Coupled Receptor 5 (TGR5) Immunometabolic Bridge

Bile acids belong in a gut-brain translation stack because they act less like a liver detour and more like endocrine wiring that couples microbial chemistry to immunity, metabolism, and vascular tone [254,255,256]. Gut microbes deconjugate and remodel primary bile acids into secondary species with different receptor potencies, so the true exposure is bile acid speciation, not “fat intake” or taxonomy [257,258,259]. These species can tune epithelial junctions, mucus and antimicrobial programs, bias macrophage cytokine output, and reshape glucose handling, which then modulates endothelial activation and perfusion stability [260,261,262]. If mood outcomes drift, this upstream chemistry may be the quiet driver, as it alters inflammatory load, energy balance, and vascular reactivity long before symptoms read out in questionnaires [254,256].

Mechanistic interpretation is cleanest when it is anchored to two receptor backbones [255,258,261]. Intestinal FXR links luminal bile acids to transcriptional programs that regulate barrier maintenance, antimicrobial tone, and the gut-liver relay via fibroblast growth factor 19 (FGF19), with downstream effects on bile synthesis, lipids, and insulin sensitivity that influence vascular risk [258,261,263]. FXR is also immunomodulatory: in macrophages and innate lymphoid cells, it can suppress inflammatory transcription when ligand tone is favorable [260,261]. In parallel, Takeda G protein-coupled receptor 5 (TGR5) functions as a bile acid-sensing GPCR that raises cAMP, dampens NF-κB driven macrophage activation, and promotes enteroendocrine glucagon-like peptide-1 (GLP-1) release, adding an incretin lever that can improve endothelial NO signaling indirectly through metabolic relief [261,264]. Treat these pathways as directional hypotheses: species that strengthen FXR feedback or engage TGR5 should track with lower inflammatory load and a less adhesive endothelium [3,260,261].

Minimum measurement should therefore be chemistry-first and time-aware. Quantify stool and plasma primary and secondary bile acids, plus key conjugates, using targeted liquid chromatography–mass spectrometry (LC-MS) panels that include cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA), ursodeoxycholic acid (UDCA), and representative glycine or taurine conjugates [257,259,265]. Report ratios that map onto microbial function and receptor tone, such as secondary to primary bile acids, DCA:CA, LCA:CDCA, and conjugated to unconjugated pools, and sample with standardized timing around meals to capture enterohepatic oscillations [257,266,267]. Add a simple “deconjugation index” and record stool pH and Bristol scale, since transit and acidity shift pools independently of the intervention [259,267]. Define success as coherent directionality, not any movement: bile acid shifts should align with reduced PRR tone and barrier leak, improved inflammatory profiles, and vascular quiescence markers [255,260,261] Pair speciation with FGF19 for FXR and GLP-1 for TGR5, then interpret against cardiometabolic context (homeostatic model assessment of insulin resistance (HOMA-IR), triglycerides, adiposity, and liver enzymes) that can otherwise masquerade as “psychobiotic” biology [254,261,263].

Bile acids cannot prove causality on their own because the same signature can reflect diet fat quality, transit time, drugs, or baseline microbiome capacity [254,255]. That is why the module needs paired intermediates: barrier markers, cytokine balance, and endothelial activation readouts that confirm the predicted chain [257,260,261]. Control protein and fat background, record antibiotics, metformin, and bile acid binders, and avoid over-reading single time points or isolated ratios [254,255,256]. With these guardrails, bile acids become a disciplined endocrine readout inside a broader mechanistic stack [254,256,262]. After endocrine mediators, the next step is discipline: neuroactive claims only count when exposure is measurable and compartment-aware.

4.4. Neuroactive Compounds and Neuromodulatory Pathways (Disciplined)

Neuroactive claims in fermented foods are useful only when posed like pharmacology: which molecule, what concentration-time curve, and which receptor or circuit are plausibly reached [165,167,268,269]. “Contains GABA” or “boosts serotonin” is not a mechanism if delivery is unmeasured and compartments are ignored [164,268,270]. Many candidates are produced in the jar but consumed, degraded, or trapped in the gut lumen, while expectancy and diet co-changes can mimic benefit [268,271,272]. Even a real peripheral shift may matter only through vascular and immune gates that set brain exposure over days, not minutes [126,200,273]. A disciplined approach therefore, treats neuroactive effects as downstream readouts of quantified exposures and intermediates, not as headlines [268,271,272]. First, verify the module that moves, then ask whether barrier, immune, and HPA indices shift in the same direction and on the same timescale [126,200,273].

What is plausible, then? Start with signals that have conserved exposure logic and peripheral gatekeeping power: SCFAs that tune inflammatory gain and vagal signaling through mucosal receptors, and Trp outputs that partition between indole ligands and KYN pathways, indexing tolerance versus immune activation [126,200,273]. Add a short list of fast, testable small molecules: GABA when strain screening plus product fingerprinting shows meaningful accumulation and stability; histamine and tyramine as dual-purpose analytes because they can be bioactive yet also confound sleep, anxious arousal, and vascular tone; and a few intermediates that repeatedly track with stress biology, such as lactate, succinate, and select catecholamine-related precursors [164,274,275]. The confound logic is central: amines, sodium, caffeine, and alcohol can shift arousal and sleep architecture directly, so any “neuroactive” claim must survive matched-comparator designs and explicit chemical assays [89,268,272].

Minimum specification follows the same stack logic. Use targeted LC–MS panels that quantify the candidate molecules and key precursors in the product an d across stool, urine, and plasma, with sampling anchored to kinetics: a post-dose window for acute signals, plus steady-state profiles after repeated intake [126,268,274]. Pair exposure with proximal pathway readouts that match the hypothesized route, for example, cortisol dynamics for HPA calibration, CRP and IL-6 for inflammatory tone, barrier leakage indices, and when feasible CNS-adjacent markers such as glial fibrillary acidic protein (GFAP), S100B, or NF-L [126,200,274]. Keep symptom endpoints domain-aligned, emphasizing sleep, fatigue, and stress reactivity over broad mood totals [269,271,274]. Small molecules are fast signals, but fermented foods also deliver larger effectors; peptides and EPS behave more like food-derived biologics and need their own logic [268,269,275].

4.5. Bioactive Peptides & Exopolysaccharides (EPS): “Food-Derived Biologics”

Bioactive peptides and EPS deserve their own module because they are product-defining effectors, closer to “food-derived biologics” than to generic nutrients [276,277,278]. Fermentation does not just preserve food; it rewrites protein and polysaccharide structures into sequences and topologies that encode signaling potential [62,277,279]. Two yogurts with identical macronutrients can carry different peptide spectra depending on strain proteases, fermentation time, and cold-chain drift, and those differences plausibly matter more than broad labels like “dairy” or “fermented” [62,280,281]. EPS follows the same rule: monosaccharide composition, branching, charge, and molecular weight function like a structural barcode that can bias mucosal and immune programs [282,283,284]. The price of this mechanistic specificity is measurement [268]. If the fingerprint is unknown, the mechanism is a story, not an exposure [268,280].

Peptide fingerprints map cleanly onto vascular endpoints when framed as directionally interpretable physiology rather than as in vitro bioactivity claims [268,285,286]. The most useful bridge is renin–angiotensin–aldosterone system (RAAS) and ACE-adjacent biology: short peptides with ACE-inhibitory motifs can lower angiotensin II pressure, tilt signaling toward the ACE2–Ang(1–7) axis, and reduce the oxidative load that collapses NO bioavailability [287,288,289]. Read the causal chain like a circuit. A peptide-rich exposure should shift NO handling (higher nitrate/nitrite with lower lipid peroxidation, improved arginine–ADMA balance), then soften adhesion programs (lower VCAM-1, ICAM-1, selectins), and finally stabilize perfusion-relevant traits such as vascular reactivity and fatigue-linked exertional intolerance [62,268,286]. Redox buffering is the parallel lane: many fermented-food peptide mixtures damp TNF-α signaling to NF-κB and p38, suppress NADPH oxidase activity, and align with nuclear factor erythroid 2-related factor 2 (Nrf2)-centered antioxidant induction [62,290,291].

EPS complements peptides by acting where the tri-barrier axis is most sensitive, at the mucosal surface [282,283]. Many EPS structures resist upper-gut digestion, persist as bioaccessible polymers, and behave as low-intensity patterning signals that can shift epithelial and myeloid tone [282,283,292]. A practical, testable prediction is that tolerogenic bias is characterized by higher secretory IgA, stronger IL-22 and antimicrobial peptide programs, and fewer PRR-amplified cytokine bursts that erode junctional organization [282,283]. EPS can also act indirectly by reshaping the ecology toward SCFA-rich guilds, which support epithelial energetics and mucus output, but the mechanistic claim should remain epithelial first, microbial second [282,283,292]. Because EPS effects are structure-dependent, “amount” is not sufficient; size distribution and charge state often explain why one product calms chemokine output while another is inert [282,283,284].

Minimum measurement should therefore look like peptidomics-lite plus EPS-aware fingerprinting, backed by functional assays and comparator discipline [268,280,281]. For peptides, quantify a targeted LC–MS panel anchored to annotated sequences or motif classes, add an in vitro digestion step to estimate bioaccessibility, and pair it with simple activity assays (ACE inhibition, dipeptidyl peptidase-4 (DPP-IV), antioxidant capacity) that serve as quality control (QC), not as endpoints [276,280,290]. For EPS, report yield, molecular-weight distribution, and basic composition (neutral vs acidic fractions), then link these to barrier and immune readouts such as TEER or FITC-dextran flux, sIgA, IL-10/IL-22, and a compact PRR-tone panel (LBP, sCD14, TNF-α, IL-6) [282,283,292]. Time-stamp exposure with early post-dose sampling plus steady-state weeks, since acute signaling and remodeling can decouple [62,268]. Confounds must be treated as design variables. Sodium alters vascular tone and sleep, and it also reroutes fermentation chemistry, so arms should be sodium-matched or sodium-measured with prespecified adjustment [268]. Biogenic amines, especially histamine and tyramine, can mimic anxiety, headache, and arousal and can move blood pressure (BP) independent of any peptide benefit; screen them alongside putrescine and cadaverine, and treat elevated batches as non-comparable exposures [268]. Match calories and protein too, because protein load can shift proteolysis and endotoxin tone [268,285].

Integration is the point: peptides and EPS should not compete with SCFAs, indoles, or bile acids; they are part of the upstream “hardware” that helps explain why those smaller molecules shift the way they do in real products [62,268,277]. A clean stack reads exposure to intermediates to integrative endpoints [268] Fingerprints define exposure; barrier and immune tone validate containment; endothelial activation and immunothrombosis report vascular translation; clocks summarize whether repeated remodeling persists [62,235,268]. This framing also makes platform choice an engineering decision and sets up phenotype stratification, because peptide and EPS effects will be louder in participants with baseline endothelial stress or inflammatory drift [62,268,285]. Yogurt and kefir are ideal for reproducible fingerprints under controlled storage, whereas miso and tempeh are powerful only if batch chemistry, sodium, and amines are tightly controlled, and fraction-enriched variants can be produced [62,276,280]. Brazilian artisanal cheeses such as Queijo Canastra and Queijo do Marajó follow the same logic as peptide/EPS “food-derived biologics,” but with greater variance and stronger confounding pressures [268,280]. They are best used as fingerprinted, batch-qualified exemplars for proteolysis-driven exposure, with sodium and histamine/tyramine explicitly screened to avoid misattributing vascular or sleep shifts to peptides [268,280]. With modules specified as measurable exposures and interpretable intermediates, platform choice becomes an engineering decision: pick the product family that best isolates the mechanism you want to test [62,268,279].

5. Immunothrombosis Chapter: Platelets + Neutrophil Extracellular Trap (NETs) + Endothelial Activation

Immunothrombosis offers a unifying vascular mechanism linking chronic stress biology and low-grade inflammation to platelet priming, NET formation, and endothelial activation, all measurable and clinically legible [293,294,295]. NETs act as DNA–protein scaffolds that trap platelets, concentrate procoagulant cues such as tissue factor, and trigger endothelial ICAM-1/VCAM-1 programs, creating a self-amplifying platelet–NET–endothelium loop [293]. This section uses that loop to motivate the relevance of depression and anxiety, specify the metabolite-to-platelet/endothelium wiring, and map food platforms and comparators that can test causality [294,295,296]. With that framing, the next subsection explains why this pathway belongs inside depression and anxiety models rather than being treated as a cardiology side note [294,297,298] (Figure 3).

5.1. Why Immunothrombosis Belongs in Depression/Anxiety

Depression and anxiety can be read as vascular stress tests: repeated autonomic and inflammatory surges push endothelium toward lower NO, higher adhesion signaling, and a more procoagulant surface, while platelets become easier to trigger [294,295,297]. The clinical payoff is subtle but pervasive. Long COVID and PASC frameworks show that low-grade thromboinflammation, with NET-linked coagulation signals, can reduce microvascular perfusion and cause fatigue and cognitive fog in people without overt cardiovascular disease [299,300,301] Sleep disruption amplifies the same physiology, as obstructive sleep apnea work illustrates through nocturnal oxidative stress, endothelial dysfunction, and daytime sleepiness [294]. ME/CFS adds a complementary pattern, where persistent cytokine tone and altered cerebral blood flow track cognitive slowing [301]. This makes immunothrombosis a mechanistic bridge between subjective symptoms and objective biology, but only if the pathway is specified as platelet, NET, and endothelial programs with defined triggers [293,302].

Immunothrombosis earns its place in depression and anxiety because it is transdiagnostic: the endothelial and platelet programs that drive cardiometabolic risk also govern microvascular perfusion, barrier signaling, and leukocyte trafficking that can shape brain-relevant outcomes [294,295,297]. Cohort and meta-analytic evidence shows depression tracks impaired flow-mediated dilation (FMD) and a circulating endothelial activation signature enriched for soluble intercellular adhesion molecule 1 (sICAM-1), MCP-1, and related adhesion cues, with stronger signals in cardiometabolic comorbidity and prospective links to symptom persistence [297,298,303]. Clinical observations add reversibility, since SSRI treatment can normalize circulating endothelial injury markers and serum-induced endothelial dysfunction [304,305,306]. On the causal side, NET biology supplies a mechanistic amplifier, and LPS models show that blocking NET formation attenuates depression-like behavior alongside reduced cytokine escalation and neuroinflammation [293,294]. This implies that mood trials can credibly test immunothrombosis when they commit to platelet and endothelial readouts, not distal events [302,307,308].

A rigorous evidentiary standard should treat immunothrombosis as a graded phenotype rather than a yes-or-no label [293,302]. The core minimum is a joint panel: platelet activation (for example CD62P, PAC-1, platelet–leukocyte aggregates or platelet factor 4 (PF4) and β-thromboglobulin), NET burden (MPO–DNA, NE–DNA, citH3, nucleosomes), and endothelial adhesion and injury signals (sICAM-1, soluble vascular cell adhesion molecule 1 (sVCAM-1), E-selectin, vWF, circulating endothelial cells), ideally summarized as a composite score since multi-marker odels outperform single analytes in vascular disease [302,304,307]. In mood populations, interpretation must be stratified by baseline inflammation, adiposity, sleep apnea, and medications, because stress alone can upshift platelet reactivity and SSRIs or antiplatelet therapy can dampen trajectories [296,305,309]. With “why it belongs” established, the next step is the wiring diagram linking metabolite modules to platelet–endothelial machinery [294,295].

5.2. Metabolite-to-Platelet/Endothelium Wiring

Metabolite-to-platelet/endothelium wiring becomes readable when you treat it like pharmacology: which receptors are being touched, and which enzymes act as bottlenecks [310,311,312]. The clearest example is phenylacetylglutamine, a microbial metabolite that boosts platelet reactivity by signaling through platelet adrenergic GPCRs, essentially hijacking catecholamine circuitry [310,313,314]. In parallel, lipid ligands such as 12(S)-HETE can amplify thrombotic signaling via platelet GPR31, while proteases remodel receptor behavior through biased PAR1 cleavage, changing the gain on downstream Ca²⁺, p38, and phosphoinositide 3-kinase (PI3K) pathways [311,312,315]. Enzyme layers matter too because platelet activation depends on metabolic checkpoints like PKM2, hexokinase, and mechanistic target of rapamycin (mTOR)-linked programs that convert substrate availability into prothrombotic phenotype [155,312,316]. This prompts a simple logic: specify the exposure class, specify the proximal vascular targets, then test whether downstream immunothrombotic outputs move in the predicted direction [302,317,318].

Different metabolite modules can converge on the same immunothrombotic outputs through distinct entry points, and that convergence is exactly why the framework works [302,315,318]. Redox tone is a master dial: NADPH oxidase 2 (NOX2), mitochondrial ROS, and myeloperoxidase (MPO) feed the oxidative chemistry required for chromatin decondensation, so antioxidant or glutathione-centric buffering can lower NET yield without needing to name every upstream trigger [155,319,320]. In parallel, NO bioavailability shapes endothelial “stickiness”; NO donors can suppress TNF-α-driven VCAM-1 and ICAM-1 via NF-κB inhibition, while nitrosative stress shifts signaling toward inflammatory gene programs [155,316,321]. A third entry point is trafficking logic, in which NETs themselves act as feed-forward cues that amplify neutrophil ROS and IL-8 release, thereby driving further NETosis and effectively recruiting more fuel to the fire [155,322,323]. Because convergence is the goal, the readout panel should prioritize shared endothelial and platelet outputs rather than chasing every upstream molecule in isolation [302,317,318].

Vascular target engagement is best demonstrated with time-aligned sampling of exposure panels alongside platelet activation indices, NET proxies, and endothelial activation markers, rather than assuming causality from microbiome shifts or symptom changes alone [302,311,317]. Practically, that means pre-specified kinetics for metabolomics and, where feasible, compartment-aware endothelial phenotyping since microvascular versus macrovascular programs are not interchangeable [155,317,324]. On the vascular side, a minimal panel can pair adhesion markers such as ICAM-1, VCAM-1, E-selectin, and endothelin-1 with platelet activation readouts such as soluble P-selectin or platelet-derived signals, complemented by a NET proxy layer when the hypothesis is immunothrombosis [302,317,325]. Comparator design is non-negotiable: compliance-matched vascular graft work is a reminder that “material differences” can masquerade as inflammation, and in food trials, sodium, calories, and co-metabolites can do the same [311,315,322].

5.3. Product Mapping

Product mapping should be hypothesis-driven, distinguishing platforms likely to deliver direct effector chemistry from those that mainly stabilize upstream ecology and barrier containment that indirectly lowers immunothrombotic tone [310,311,322]. A useful heuristic is to separate “drivers” from “enablers.” Drivers are platforms that reliably carry a defined payload, like metabolite-rich fractions or engineered delivery systems, where structure-centered design is explicitly used to overcome biological barriers and improve target engagement [310,311,322] Enablers, in contrast, act more like governance layers in an ecosystem: they increase stability, reduce noise, and shape interactions, yet they do not themselves guarantee a strong effector signal [316,320,326]. Treating foods as modular platforms forces the same question asked in other ecosystems: what is standardized, what drifts, and where does leverage actually come from [315,322,326]. The Brazilian case studies are included to operationalize this point: they exemplify how regional products can be translated into measurable exposures and interpretable intermediates without requiring encyclopedic coverage [314,315,322]. In that sense, they are not detours, but templates for discovering and evaluating “unknown” fermented foods worldwide [314,322,326] This framing supports a tiered testing strategy, where the first objective is to verify module engagement and the second is to assess whether immunothrombosis endpoints respond in the predicted direction and with the predicted kinetics [302,317,318].

Because fermented foods co-deliver vascularly active confounders, product studies should report sodium and biogenic amines and use matched comparators, such as live versus heat-treated or metabolite-enriched variants, with energy and salt held constant [315,322]. Sodium is not just a background nutrient in fermented matrices; it can reshape microbial ecology and, in turn, biogenic amine accumulation, as shown in controlled fermentation models where higher NaCl shifts communities and lowers histamine/tyramine-related load [315,322]. Biogenic amines then become interpretation-critical because they can perturb vascular tone, sleep, and neurovegetative symptoms in ways that mimic “benefit” or “harm” independent of the intended module [315,322]. A minimal checklist therefore, includes per-serving NaCl, quantified histamine and tyramine, and a comparator hierarchy that perturbs only one axis at a time: culture viability, module enrichment, or amine depletion [315,322]. With this discipline, product effects can be credibly attributed to verified metabolite-module engagement and aligned to endothelial and BBB-relevant outcomes rather than to uncontrolled dietary drift [317,318,322] (Table 4).

6. Epigenetic Clocks + Biological Aging Endpoints

Epigenetic clocks are algorithms that estimate biological age, and age acceleration marks when that estimate runs ahead of chronological age [344]. Because clocks compress immune tone, metabolic stress, and vascular dysfunction into a single quantitative signal, they act as an integrative endpoint for linking mood symptoms to endothelial and inflammatory biology in a mechanism-first framework [349]. Here, clocks function like an odometer for remodeling pressure: if fermented-food metabolite modules truly stabilize barrier and vascular programs, biological aging trajectories should shift in a coherent direction across individuals [175,350]. The next subsection explains why clocks are particularly useful in depression and anxiety research, where heterogeneity makes single biomarkers easy to misread, before turning to plausible metabolite routes into methylation dynamics and then to trial-ready product mapping and endpoints [350,351].

6.1. Why Clocks Are Useful Here

In a mechanism-first framework, epigenetic clocks function as “remodeling time” readouts that capture whether repeated exposures actually shift organism-level set points rather than producing transient biomarker noise [344,347,352]. Longitudinal clock trajectories are therefore more informative than single cross-sectional age gaps, because they can register durable recalibration in immunometabolic and vascular programs even when CRP, lipids, or glucose wobble with sleep, diet, or acute stress [347,352]. Different clocks emphasize different constructs, from chronological age approximation to mortality-linked pace measures, so a meaningful change mechanistically implies altered aging rate signals aligned with nutrient sensing, mitochondrial function, immune composition, and other hallmarks [344,353,354]. This is especially valuable in depression and anxiety because biological aging signals are not uniform across patients, so the question becomes who shows acceleration and why [37,353,355,356].

Depression and anxiety show biological aging patterns in subsets, where inflammatory tone, sleep disruption, metabolic risk, and medication context plausibly determine whether methylation trajectories drift toward acceleration or remain resilient [353,355,356,357]. Large cohorts report only modest average acceleration in major depressive disorder (MDD), yet the signal strengthens in higher-severity and childhood-adversity profiles, and in never-medicated active disease with immune shifts such as lower DNAm-inferred NK cells [353,356]. Anxiety adds its own twist: subtype and social-functioning context can align with suppressed or altered aging signals rather than uniform acceleration [349,355]. Next-generation clocks often track transdiagnostic internalizing liability more than any single syndrome, while insomnia-defined male mood-disorder groups show striking GrimAge acceleration tied to cardiometabolic proteins [354,355,357]. Once subsets are explicit, the mechanistic question sharpens to how microbial metabolites and fermented-food modules might plausibly nudge methylation control systems in those at-risk phenotypes.

6.2. How Microbial Metabolites Plausibly Touch Methylation Trajectories

SCFAs offer a clean mechanistic entry point because they behave like chromatin-active exposures rather than passive fuels. Butyrate and propionate can inhibit class I/II HDACs, yet they also act as acyl donors that activate p300 and write histone acylation marks, including butyrylation, propionylation, and crotonylation at open regulatory regions that control large transcriptional programs [358,359]. That architecture makes it plausible that sustained SCFA patterns could shift the transcriptional “guard rails” that stabilize methylation trajectories over time [360,361]. The most convincing intermediates are therefore proximate and time-aligned: histone acylation panels, p300 and HDAC activity readouts, chromatin accessibility, DNMT expression, and immune-cell fate shifts such as Th17 to Treg or B-cell differentiation [360,362,363]. However, chromatin plausibility is not enough, so the next step is to treat inflammation reduction as a key “clock input” that can mediate durable remodeling across immune and vascular compartments [363,364,365,366].

A lower inflammatory load is the most interpretable route to slower biological aging because cytokine tone is not just a correlate; it is a repeated stimulus that keeps hematopoiesis in “alarm mode” and pressures the epigenome toward wear-and-tear remodeling [363,364,366,367]. Large cohort data show that a latent systemic inflammation factor aligns with epigenetic age acceleration across many clocks and forecasts mortality, while geroscience syntheses place inflammaging upstream of senescence, mitochondrial stress, and immune decline [365,366,367,368]. Mechanistically, chronic IL-6, TNF-α, CRP, and related mediators can bias immune cell composition, amplify oxidative and circadian stress, and sustain pro-aging transcriptional programs [363,366,369]. To make clock shifts interpretable, trials should co-measure cytokines and acute-phase markers, immune-cell proportions, NLR-type indices, and immunosenescence panels. This makes endothelium a critical intermediate, since vascular cells both sense inflammatory traffic and express senescence-like programs that can feed back into systemic aging signatures [200,368,370,371].

Endothelial senescence-like activation programs, reflected in NO imbalance, redox stress, and adhesion signaling, provide a biologically plausible bridge from gut-derived exposures to epigenetic aging readouts because they sit where inflammation, perfusion, and barrier function collide [200,363,368,371]. Endothelial cells are continuously “sampling” circulating chemistry, so metabolite modules can plausibly inscribe aging signals through SIRT1, AMPK–mTOR, NRF2, and p53/p21 pathways that reshape permeability, vasodilatory reserve, and SASP-like cytokine output. Direct examples strengthen the logic: a gut flora–dependent metabolite such as TMAO can accelerate endothelial senescence via oxidative stress and SIRT1 repression, while broader vascular-aging syntheses highlight metabolite-sensitive control of NO and inflammatory adhesion programs [200,363,371,372]. Practically, endothelial senescence signatures and vascular function measures should be co-primary with clocks, so products are chosen for their ability to move both panels. With these mechanistic paths defined, platform selection can be made hypothesis-driven, choosing foods that reliably deliver the exposure modules needed to test clock and vascular remodeling in trials.

6.3. Product Mapping and Trial Endpoints

Yogurt and kefir are the most trial-friendly platforms for epigenetic clocks because they already come with a playbook for standardization: defined starter consortia, controlled fermentation kinetics, stable cold-chain storage, and high adherence when dosing is daily and food-like [103,373]. That matters if clocks are treated as “remodeling time” signals that benefit from repeated, time-resolved sampling rather than one-off snapshots [103,373]. The minimum mechanistic fingerprint should pair untargeted metabolomics with targeted SCFAs, plus optional peptide and exopolysaccharide signatures when strains are selected for bioactive release [44,103,374] . On the outcome side, clocks can be stacked with inflammatory load (hs-CRP, IL-6), endothelial aging panels (sICAM-1, sVCAM-1, vWF, selectins), and a functional readout such as FMD [195,375]. This enables comparator designs that isolate live, heat-treated, and metabolite-enriched variants while preserving energy and sodium matching, creating clean tests of clock and endothelial remodeling [103,195].

Fermented vegetables and soy ferments fit best as adjunct arms or controlled dietary backgrounds, where vegetables stabilize ecology and barrier tone, while soy can add high-information peptides and biotransformed phytochemical exposure if batch chemistry is fingerprinted and variability is constrained [44,195,376]. Pilot and crossover studies suggest that vegetable ferments shift butyrate-associated taxa and gut community structure with modest systemic inflammatory change, which is useful for “ecology support” but risky if sourcing, salt, and fermentation parameters drift [44,374]. Soy, by contrast, has clearer, biomarker-dense signals in RCTs, including lipid and metabolic changes, and even effects on cognition in older adults, yet its effects can hinge on matrix and responder status, such as equol production [91,377,378]. Both platforms therefore, need lot-level metabolomics plus sodium and biogenic-amine reporting when relevant, and a design that fixes background intake or stratifies it explicitly [44,103]. With platform roles clarified, the section can specify a core endpoint panel that treats clocks as integrative outcomes and vascular, immune, and metabolite measures as the mechanistic scaffolding needed for causal interpretation [103,375].

7. Evidence Map: What Exists and What’s Missing

This section is a readiness audit: it scores psychobiotic and fermented-food evidence by how well it turns “gut–brain” claims into testable biology. The map is organized as a causality ladder, then a catalogue of failure modes, and finally a platform summary, because efficacy without mechanism often reflects dosing noise, unmeasured metabolites, or uncontrolled diets rather than true pathway engagement. “Missing” evidence here means absent target or exposure verification, absent proximal biomarkers, or designs that cannot falsify the proposed mechanism. The ladder starts at the lowest rung, where endothelial and BBB models can specify targets and outputs with minimal clinical noise.

7.1. Causality Ladder

In vitro endothelium and BBB systems are the cleanest places to test receptor and enzyme engagement, because exposure can be clamped and proximal outputs, such as eNOS signaling, permeability, glycocalyx injury, and adhesion programs, can be read directly [379,380]. Modern BBB microvessels, organoids, and chips achieve low baseline leakage with high TEER, tight junction markers like claudin-5 and ZO-1, and functional efflux transporters, letting you quantify module effects on barrier tightening or disruption with dextran or albumin tracers [380,381,382]. They also support decisive engagement assays, including transferrin receptor or LRP1 transcytosis and chemokine-guided immune trafficking [380,381,382]. Mood inference is indirect, so mitigation is to pair these readouts with exposure metabolomics and then escalate [383,384]. Once a module moves these programs in the predicted direction, the next rung asks whether the same biology remains causal in living systems that include immunity, perfusion, and behavior [379,385].

Animal studies earn their rung only when they demonstrate directionality, ideally by showing that the intervention shifts platelet, NET, or endothelial programs and that blocking a defined node abolishes both the vascular phenotype and the depression or anxiety-like behavior [186,385]. The strongest designs look less like “probiotic improves behavior” and more like circuit tests: a metabolite-competent strain rescues stress phenotypes, the same strain with a knocked-out biosynthetic gene loses efficacy, and pathway blockade or rescue (for example, AhR signaling for ILA, or experimentally induced BBB opening) toggles both neuroinflammation and behavior [379,385]. Behavioral readouts still matter, but they should be bracketed by intermediates, including barrier integrity, cytokine tone, and vascular transcriptomic signatures, with timing matched to exposure kinetics [186,379]. Even strong animal causality still leaves a translational gap, so the next step is human feeding work designed to capture time-resolved exposure and proximal biology before symptom claims [383,384].

Short mechanistic feeding studies are the best human bridge because they can verify exposure chemistry, quantify immediate platelet and endothelial responses, and map kinetics in blood, stool, and urine before outcomes are diluted by weeks of life noise [383,384,386]. The strongest examples already pair intake with objective fingerprints, such as 16S plus fecal metabolomics in strain trials and metagenomics with urine and fecal metabolite panels in psychobiotic diet work, so “what was delivered” and “what moved” are both visible [384,387]. The minimum design then adds time-stamped vascular biology: platelet activation indices, endothelial adhesion and permeability markers, and aligned inflammatory and endocrine signals such as CRP, IL-6, and cortisol [186,384]. If these studies show consistent proximal movement, the field has earned the right to scale into RCTs that treat immunothrombosis and aging endpoints as quantifiable phenotypes [186,383].

RCTs become mechanistic when they preserve tight comparators, verify strain identity or processing differences, and pair symptom outcomes with an endpoint stack that includes metabolite fingerprints, endothelial activation markers, platelet or NET indices, and integrative clocks [383,384]. The most informative psychobiotic trials already hint at this architecture: multi-strain designs that show shifts in hs-CRP, cortisol awakening response, glutathione, IL-6, serotonin, stool metabolomes, or SCFA-producing taxa make it clear the intervention did something biological even when between-group symptom separation is modest [384]. Credibility then hinges on adherence verification and matched controls, including heat-killed versus live cells, matrix-matched placebos, and factorial diet designs that prevent background drift from mimicking “effects” [383,384]. The problem is that many trials skip these elements, so the next subsection names the recurring failure modes that make null results uninterpretable [383,384].

7.2. Why Trials Often Fail (Mechanistically)

Many psychobiotic trials collapse at the chemistry layer because, without starter verification, viability or heat-treatment confirmation, and basic metabolomics or targeted panels, the intervention is a label rather than a measurable exposure [8,388]. Reviews of RCTs repeatedly show that strains, doses, and formulations are poorly harmonized, and that “probiotics” are often treated as a generic class rather than a defined chemotype with trackable outputs [6,8] Minimal QC should include strain ID confirmation, CFU stability across storage, documentation of inactivation when claimed, and a fingerprint that can be reproduced across batches (untargeted metabolomics or a targeted set spanning SCFAs, indoles, lactate, and key amino-acid derivatives) [388]. When these elements are missing, null results cannot distinguish biological failure from exposure failure, and positive signals do not replicate [8,388] Even with verified products, effects can still be washed out or misattributed when confounders and participant heterogeneity are not engineered out of the design [8,388].

Mechanistic failure often reflects preventable noise, including sodium load, histamine and tyramine exposure, calorie mismatch, medication background, and uncontrolled fermented-food intake, layered onto unstratified depression and anxiety subsets with very different inflammatory and metabolic baselines [8,389,390]. Diet can remodel metabolites and the microbiota within days, while “microbiome resilience” and person-level factors can swamp short interventions, so weak controls can yield both false negatives and spurious wins [388,389]. Reviews in youth and mixed psychiatric samples repeatedly flag small cohorts, variable baseline severity, and heterogeneous products as the recipe for nulls that teach nothing, while pharmacomicrobiomics data add a further confound because psychotropics can shift the microbiome and response propensity [8,389,390] The fix is boring but decisive: sodium and amine reporting, calorie matching, lead-in stabilization, adherence biomarkers, and stratification by sleep, adiposity, inflammation, and medication [8,389]. These constraints set up a final, practical question: given the evidence and failure modes, which product families are best positioned for mechanism-first trials, and which should be positioned as adjuncts [389,391].

Clinically, the most defensible role for fermented foods at present is as adjunctive, mechanism-aligned interventions, especially in patients with inflammatory, metabolic, or neurovascular features [389,391]. Translation should therefore move away from generic advice to “eat more fermented foods” and toward matrix-specific selection based on biochemical profile, tolerability, and measurable target engagement [172,389,391,392,393]. Within that framework, fermented vegetables are most naturally aligned with barrier reinforcement and endotoxemia reduction, dairy with standardized peptide/EPS delivery and endothelial-redox hypotheses, and soy with peptide-rich immunometabolic and bile-acid-linked mechanisms [391,394,395]. Practical implementation should be framed in terms of dose, duration, timing, and biochemical tolerability rather than solely on food identity [391]. Moderate daily exposures sustained over several weeks are more plausible than acute dosing for ecological and metabolic adaptation, but sodium load, biogenic amines, gastrointestinal sensitivity, and sleep-related tolerability must be considered, as they can alter vascular tone and symptom perception [172,391,392,393,395].

Fermented foods should not be positioned as substitutes for pharmacological or psychotherapeutic treatment [8,389]. Their more plausible role is as systems-level adjuncts capable of modulating upstream drivers such as inflammation, barrier dysfunction, and metabolic dysregulation, thereby potentially improving resilience and treatment responsiveness within a precision nutritional psychiatry framework [8,172,389,391,393,396,397,398,399,400]. Long-term effects remain poorly characterized [8,389,391]. Chronic intake may induce more sustained shifts in microbiota function and metabolite production, but adaptive microbial and host responses could also attenuate effects over time, making the durability of benefit an open mechanistic and clinical question [389,391,401]. Longitudinal studies are therefore needed to determine whether continuous intake, cycling, or diversification of fermented foods best sustains benefit, and whether adherence, cultural acceptability, and safety constrain real-world implementation in specific patient groups [389,391]. Fermented foods should also be contextualized within broader dietary and therapeutic strategies [8,389,391]. Mediterranean-style and other anti-inflammatory dietary patterns likely provide a permissive background for fermented-food effects, whereas fiber supplementation may reproduce only part of the mechanism by increasing SCFA availability without the added peptide, EPS, and fermentation-derived chemical complexity [391,402,403,404]. Compared with probiotic capsules, fermented foods offer a more ecologically valid but less standardized exposure, and this trade-off becomes even more complex when concurrent antidepressant or other medications alter microbiome composition and metabolism [389,390].

Even with rapid expansion of mechanistic insight, the clinical evidence base remains heterogeneous and at times inconclusive [8,389,405]. That mismatch between mechanistic richness and trial interpretability explains why product-family readiness must be judged not only by biological plausibility but also by exposure control, target engagement, and phenotype alignment [388,389]. Randomized trials and meta-analyses have generally shown modest, variable effects for probiotic-rich interventions on depressive symptoms, stress reactivity, and sleep, with the signal appearing more convincing in clinically defined populations than in broadly mixed samples [8,405]. Yet heterogeneity across strains, doses, matrices, and trial design sharply limits interpretation, reinforcing the need to treat positive and null findings as information about exposure fidelity rather than as simple verdicts on “probiotics” or “fermented foods” [6,8,388]. Whole fermented foods remain underrepresented in controlled trials relative to capsule-based probiotics, creating a persistent translational gap between real dietary exposures and mechanism-first hypotheses [389,391]. Closing that gap will require human studies that define the food matrix as carefully as the clinical phenotype [389,391,406,407,408]. A central limitation is that many studies still do not verify whether candidate metabolite modules—such as SCFAs, indoles, bile acids, peptides, or EPS-linked signatures—were actually engaged [388,391]. Without exposure verification, symptom outcomes alone provide only weak causal inference, especially when products differ in chemistry, viability, sodium content, and storage history [8,388].

7.3. Product-Family Summary of Evidence Readiness

Fermented vegetables are increasingly plausible as ecological stabilizers, nudging taxa, organic acids, and, occasionally, GABA in ways that may support barrier tone, yet their readiness is constrained by batch-to-batch microbiology, salt variability, and the ever-present risk of biogenic amines or other process byproducts [409,410,411]. Fermented soy is biologically denser: isoflavone biotransformation, peptide release, and product-specific neuroactive signatures can generate high-information signals, but these effects ride on cultural dietary baselines, equol-responder status, and process-driven divergence even within a single named product family [195,412,413]. To use either without drift, trials need a starter or consortia definition, metabolomic fingerprinting, sodium and amine reporting, and tight background-diet control with phenotype stratification [44,410,414]. This contrast explains why dairy often becomes the anchor platform, since it best supports standardized dosing, clean comparators, and dense mechanistic sampling [44,103].

Yogurt and kefir are the most evidence-ready platforms because dairy fermentation is unusually controllable: starters can be specified, viable counts and storage can be standardized, and dosing can be repeated with high adherence and tolerability [44,103]. That feasibility is not just logistical, it is causal leverage, since tight matrix control makes it realistic to link a defined strain–metabolite fingerprint (SCFAs, peptides, other postbiotics) to aligned shifts in inflammation, barrier tone, and vascular or immune activation, then read any downstream movement in aging panels or symptom trajectories in the same cohort [44,215,374]. In other words, dairy turns “psychobiotics” from a brand label into a measurable exposure with interpretable biology [44,374]. With the evidence ladder, failure modes, and platform readiness clarified, the next section can move from mapping to execution by specifying the minimal design template for mechanism-first psychobiotic trials [44,374].

8. Translation Playbook: Next-Generation Study Designs

A translation playbook is needed because the psychobiotics literature still too often trades on promise without pinning down what actually moves in the body. Across reviews and proposed pipelines, the same bottlenecks recur: heterogeneous products, weak strain or matrix attribution, and mechanistic readouts that are missing or incomparable, especially for metabolites whose quantification is technically demanding and timing-sensitive. The field remains constrained by heterogeneity in product composition, limited exposure verification, and weak alignment between mechanistic and clinical endpoints. The playbook solves this by standardizing what counts as evidence, then operationalizing it into panels, comparator templates, and phenotype stratification that can survive replication and regulation [415,416]. The starting point is a minimal mechanistic panel that treats exposure as measurable chemistry and biology as a linked stack rather than isolated endpoints [351,415,416] (Table 5).

8.1. Minimum Mechanistic Panel (For Publishable Causality)

A “minimum” mechanistic panel should be publishable because it is vertically integrated, not exhaustive: it verifies exposure modules first (strain identity plus a metabolite fingerprint such as SCFAs and Trp /indole derivatives), then reads the next dominoes in tissues that transmit gut signals [436]. Barrier integrity (permeability markers and tight-junction-linked readouts) determines whether luminal chemistry can plausibly reach the circulation [437]. Endothelial activation and platelet or NET indices then translate immune traffic into a vascular phenotype with clear directionality [438]. Finally, integrative endpoints like immunothrombosis composites and epigenetic aging pace summarize accumulated wear [439]. That chain begins with exposure verification, because without a quantified metabolite and strain signature, downstream biology cannot be attributed [440].

Metabolite modules serve as the anchor because they turn food interventions into measurable dosing: you fingerprint the product at baseline, then track time-resolved signatures in stool, urine, and blood to confirm delivery, absorption, and host handling, rather than assuming “one serving” is a unit of exposure [436]. Minimal coverage can stay lean but must be interpretable, typically SCFAs, Trp, and indole derivatives, key biogenic amines, and a compact bile acid or phenolic panel, read with attention to kinetics and compartment logic [441]. In this framing, “dose” is the achieved concentration time-course plus its reproducibility across batches and participants [442]. Once exposure is real, the next question is whether it shifts the gut barrier and immune traffic that often mediate systemic vascular and mood-relevant biology [443].

The barrier module should quantify permeability and mucosal immune tone because small changes in microbial translocation can amplify cytokine signaling, nudge coagulation tone, and prime vascular activation, creating downstream noise that looks like mood biology but is really immune traffic [444]. Minimum outputs should separate “pore” versus “leak” behavior, then pair these with translocation proxies and a compact cytokine set that includes both drivers and brakes, so you can tell barrier opening from generic inflammation [445]. Add one epithelial repair or stress marker to distinguish injury from remodeling [446]. If barrier readouts move in the predicted direction, endothelial phenotypes become the next mechanistic checkpoint linking circulating exposures to perfusion, adhesion programs, and aging signatures [446].

Endothelial readouts should capture the balance between NO signaling, redox stress, and adhesion activation, since this triad translates inflammatory load into perfusion and barrier-function consequences that can propagate into whole-body aging and brain vulnerability [447,448]. A minimal panel can stay lean: one vasodilatory axis marker, plus a redox pair that reflects oxidative burden and antioxidant capacity; then an activation set anchored on VCAM-1 or ICAM-1, with an endothelial microparticle or glycocalyx-injury proxy [447,449]. Directionality should be explicit: higher NO bioavailability with lower oxidative markers and reduced adhesion signals indicates de-activation, while the opposite pattern flags senescence-like programming and SASP drift [368,450]. Because endothelial activation often travels with immunothrombosis, the panel should next quantify platelet and NET-linked programs that operationalize vascular risk biology [447,451].

Platelet activation markers and NET-related indices provide a high-signal readout of immunothrombosis that is mechanistically close to endothelial stress, sensitive to inflammatory tone, and feasible to measure repeatedly in short and long trials [18,452] This module matters because platelets can trigger NETosis and then get trapped in NET scaffolds, creating a feed-forward thromboinflammatory loop that is targetable, not just correlative [18,453]. Minimum feasible markers can stay pragmatic: soluble P-selectin or platelet–monocyte aggregates for platelet activation, PF4 as a platelet release signal, and a NET core such as MPO–DNA or citrullinated histone H3, optionally paired with vWF and ADAMTS13 as a functional hinge [335]. With exposure, barrier, vascular activation, and immunothrombosis quantified, epigenetic clocks can be interpreted as an integrative “pace” endpoint rather than a decorative add-on.

Clocks should be treated as longitudinal pace indicators that summarize whether repeated exposures and intermediate pathway shifts actually remodel system-level set points, with interpretation anchored to concurrent changes in inflammation, endothelial state, and immune cell composition. A meaningful shift is not “age reversal” on paper, but a reproducible change in a morbidity-linked pace measure that tracks in the same direction as improved barrier integrity, lower cytokine tone, and quieter vascular activation [368,452]. Clock selection should be purpose-built: pair one mortality or phenotypic clock with a process-leaning option, and repeat both to separate signal from cell-mixture drift. Read them like a dashboard, not a verdict. Once the minimal panel is fixed, trial design becomes a question of product-centered comparators that isolate live microbes, postbiotic chemistry, and matrix effects.

8.2. Three Trial Templates (Product-Centered)

A yogurt or kefir template works best as a three-arm design: live fermented product, pasteurized after fermentation, and a chemically acidified dairy control matched for calories and pH [454,455]. Adherence is tightened with portioned servings and container returns [454,455]. Verification must be dual: strain tracking in stool to test passage or engraftment, plus LC–MS fingerprints of peptides, acids, and microbial metabolites in product and urine or plasma as the dose readout [454,456]. Endpoints map to the causal question: if only live shifts barrier, endothelial, or immunothrombosis modules, colonization matters; if pasteurized matches it, postbiotic chemistry is sufficient [454]. If dairy yields a low-noise signal, plant ferments can follow with sodium, amine, and batch controls [456]. A low-expansion extension is to treat selected artisanal cheeses (e.g., Canastra, Marajó) as a peptidome-forward dairy subcase, only when matched for sodium and batch-certified for biogenic amines [456,457]. That keeps the dairy logic intact while letting peptide-rich matrices be evaluated without inflating the design [454,456].

A kimchi or sauerkraut template should be engineered like a dosing study, not a cultural food swap: fixed calories, fixed fiber, and sodium either low or deliberately clamped to a narrow target so salt-driven hemodynamics cannot masquerade as “psychobiotic” biology [458]. Each batch needs release criteria, including starter-consortium identity, viable counts, and a metabolomic fingerprint that explicitly quantifies lactate, acetate, GABA, and biogenic amines such as histamine and tyramine, then tracks their kinetics in stool, urine, and blood through standardized storage and shelf-life [456,458]. Mechanistic “success” is directional, not poetic: reduced permeability and inflammatory traffic, plus quieter endothelial activation, at unchanged sodium exposure [454,459]. For soy ferments, the handle shifts toward peptide and phytochemical transformation, so fractionation and immunometabolic readouts become central [454,458]. Cassava ferments can serve as a complementary plant-ferment template, with the dominant knob being starch remodeling and acidification, not sodium-driven hemodynamics [458]. Tucupi and puba/carimã are especially useful when the goal is to link defined organic-acid exposure and substrate steering to permeability and PRR-tone readouts under standardized storage and batch chemistry [458,459].

8.3. Stratify by Phenotype

Phenotype stratification is the antidote to “average-effect” ambiguity. Pre-specify four high-yield strata: inflammatory depression, anxious arousal, metabolic-syndrome comorbidity, and a sleep-disturbed subtype, because each plausibly locks in baseline cytokine tone, endothelial stress, platelet reactivity, and clock pace that governs whether a psychobiotic can move the mechanistic stack. Use PATH-style principles of predictive heterogeneity by defining strata based on multivariable risk and effect models, then report absolute effects within strata rather than fishing for one-variable subgroups [34]. This turns null results into interpretable evidence and often improves power through prognostic enrichment [460]. With strata pre-specified and the mechanistic panel fixed, the next step is to formalize a minimal design template that researchers can reuse across products and populations [351]. This is especially important because inflammatory and non-inflammatory depressive phenotypes, as well as cardiometabolic comorbidity states, are unlikely to respond equally to barrier-, peptide-, or bile-acid-dominant interventions. Baseline microbial diversity and metabolic comorbidity should also be considered response modifiers, because identical fermented-food exposures may yield very different metabolite outputs across obesity, insulin resistance, hypertension, and low-diversity microbiome states [461] (Figure 4).

9. Conclusions

This review frames fermented foods as metabolite engineering platforms rather than cultural labels, and argues that depression and anxiety become mechanistically legible when placed on a tri-barrier remodeling axis linking gut containment, systemic endothelium and platelet biology, and BBB neuroimmune gating [6]. By prioritizing module-defined exposures, including SCFAs, Trp indoles, bile acids, selected neuroactive intermediates, and peptide plus EPS fingerprints, the synthesis turns broad diet narratives into dosing-grade hypotheses that can be tested, falsified, and iteratively improved [6]. The main practical advance is a reusable stack: quantify exposure, demonstrate proximal target engagement at the barrier, then test vascular translation through adhesion programs, NO and redox balance, and immunothrombosis before asking symptoms to move [462]. Future work should standardize products and comparators, control sodium and biogenic amines, and pre-specify phenotype strata so heterogeneous responses strengthen inference rather than dilute it [415]. Future work should also test fermented foods within real dietary patterns, because ecological context is part of the exposure, not merely background noise [6]. Methodological priorities include compartment-aware kinetics, harmonized multi-omics pipelines with transparent QA, and longitudinal endpoints that track biological pace alongside domain-specific outcomes such as sleep disruption and anxious arousal. With these upgrades, regional platforms such as Brazilian cassava ferments and artisanal cheeses can sit alongside globally familiar products, improving external validity while maintaining tight causal attribution [416] (Table 6).